Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The Mitogen-Activated Protein (MAP) Kinase pathway contains oncogenic genes crucial for cancer development.
• Identifying mutations within this pathway can reveal potential therapeutic targets for lung adenocarcinoma (ADCA).

Purpose of the Study:

• To analyze mutations in the MAP Kinase pathway in Indian ADCA patients.
• To correlate these mutations with clinico-pathologic features and survival outcomes.
• To investigate the co-occurrence of mutations in key genes like EGFR and KRAS.

Main Methods:

• Retrieved and analyzed 125 pulmonary ADCA cases from the last five years.
• Assessed histo-morphology and tumor content.
• Utilized Sanger sequencing and Real-time PCR to analyze EGFR, KRAS, BRAF, and MEK1 genes.
• Performed clinico-pathologic correlation and survival analysis.

Main Results:

• 46.4% of patients had genetic mutations; 49% had single somatic mutations, 5% multiple exonic, and 4% coexisting EGFR and KRAS mutations.
• EGFR mutations were found in 24.8%, KRAS in 19.2%, and BRAF (non-V600E) in 2.4% of cases.
• No significant difference in progression-free survival was noted between wild-type/single mutations and multiple/coexisting mutations (P=0.09).

Conclusions:

• EGFR and KRAS mutations can coexist in the same lung ADCA patient.
• Multiple exonic KRAS mutations represent a significant portion of the cohort, warranting further investigation.
• Lung ADCA with BRAF mutations are often non-V600E.
• Comprehensive testing for major genetic driver mutations in lung ADCA is essential, regardless of histology or demographics.